Stockscreener 앱 받기
14.81
0.47%
0.07
시간 외 거래:
14.94
0.13
+0.88%
전일 마감가:
$14.74
열려 있는:
$14.66
하루 거래량:
2.48M
Relative Volume:
1.32
시가총액:
$1.51B
수익:
-
순이익/손실:
$-804.34M
주가수익비율:
-1.5739
EPS:
-9.41
순현금흐름:
$-531.06M
1주 성능:
-5.31%
1개월 성능:
-33.05%
6개월 성능:
-67.81%
1년 성능:
-57.96%
1일 변동 폭
$14.33
$15.18
1주일 범위
$14.33
$15.94
52주 변동 폭
$14.33
$55.70
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
BHVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
14.81 | 1.60B | 0 | -804.34M | -531.06M | -9.41 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
Biohaven stock hits 52-week low at $14.36 amid market challenges - Investing.com Australia
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target By Investing.com - Investing.com India
Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments - TipRanks
Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements - TipRanks
Investors in Biohaven Ltd. (BHVN) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Cowen reiterates Buy on Biohaven stock, maintains $75 target By Investing.com - Investing.com India
Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - marketscreener.com
Biohaven initiates global Phase 2/3 study of BHV-8000 - TipRanks
Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News - GuruFocus
TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN' - StreetInsider
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - PR Newswire
Biohaven’s BHV-1400 shows promise in IgA nephropathy treatment By Investing.com - Investing.com South Africa
Optimistic Buy Rating for Biohaven Ltd. Amid Promising Pipeline and Regulatory Challenges - TipRanks
Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating - TipRanks
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class - The Malaysian Reserve
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors - The Malaysian Reserve
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Trea - StreetInsider
Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy - Insider Monkey
Biohaven’s BHV-1400 shows promise in IgA nephropathy treatment - Investing.com Australia
Biohaven (BHVN) Advances Innovative Drug Trials for Immune Diseases | BHVN Stock News - GuruFocus
Biohaven (BHVN) Reports Promising Phase 1 Results for Cancer Tre - GuruFocus
Biohaven Pharma (BHVN) Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day - StreetInsider
Biohaven says anti-cancer agent cut tumor size with Regeneron’s Libtayo in Phase 1 trial - Seeking Alpha
Lost Money on Biohaven Ltd. (BHVN)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Biohaven Ltd. Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and Fgfr3 Antibody Drug Conjugates Incorporating Novel Topoix Payload with Potential to Treat A Wide Variety of Tumors - marketscreener.com
Biohaven (BHVN) Reports Promising Early Results in Oncology Prog - GuruFocus
Biohaven’s BHV-1510 shows promise in early cancer trial By Investing.com - Investing.com India
Biohaven’s BHV-1510 shows promise in early cancer trial - Investing.com
Biohaven Presents Oncology Program Updates And Preliminary Clinical Data - marketscreener.com
Biohaven Pharma (BHVN) Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates - StreetInsider
Breakthrough: Biohaven's New Cancer Drug Achieves Perfect Response Rate in First 6 Patients Treated - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd.BHVN - Longview News-Journal
Inozyme Pharma and Biohaven Pharmaceuticals Announce Leadership Changes Amid Industry Restructuring - geneonline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - GlobeNewswire Inc.
(BHVN) Long Term Investment Analysis - news.stocktradersdaily.com
Biohaven’s SWOT analysis: stock faces regulatory hurdles amid pipeline potential - Investing.com Nigeria
Biohaven (NYSE:BHVN) Downgraded by Royal Bank of Canada to Sector Perform - Defense World
Biohaven (BHVN) Sees Downgraded Rating and Lowered Price Target - GuruFocus
RBC Downgrades Biohaven Amid Market Valuation Concerns - Finimize
Biohaven Has Lots Of Shots, Too Many Risks, RBC Says - marketscreener.com
Biohaven (BHVN) Downgraded by RBC Capital with Price Target Cut | BHVN Stock News - GuruFocus
Biohaven (BHVN) Receives Downgrade Amid Regulatory Concerns | BH - GuruFocus
RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $21 From $54, Keeps Speculative Risk - marketscreener.com
RBC downgrades Biohaven to Sector Perform on regulatory risk - TipRanks
41,762 Shares in Biohaven Ltd. (NYSE:BHVN) Purchased by BNP Paribas Financial Markets - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. ... - Eagle-Tribune
In Brief: US FDA Delay Sends Biohaven Shares Down - insights.citeline.com
Healthcare Shake-Up: UnitedHealth And Biohaven Face Setbacks - Finimize
Biohaven (BHVN) Shares Dip as FDA Extends Drug Review Timeline - GuruFocus
Royal Bank of Canada Cuts Biohaven (NYSE:BHVN) Price Target to $54.00 - Defense World
Biohaven (NYSE:BHVN) Upgraded at Cantor Fitzgerald - Defense World
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):